{"id":"tysabri-and-avonex","safety":{"commonSideEffects":[{"rate":null,"effect":"Progressive multifocal leukoencephalopathy (PML)"},{"rate":"Approximately 10-20%","effect":"Infusion reactions"},{"rate":"Approximately 30-40%","effect":"Headache"},{"rate":"Approximately 25-35%","effect":"Fatigue"},{"rate":"Approximately 50-60%","effect":"Flu-like symptoms (AVONEX)"},{"rate":"Approximately 30-40%","effect":"Injection site reactions (AVONEX)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TYSABRI (natalizumab) is a monoclonal antibody that binds α4-integrin on lymphocytes, preventing their adhesion to vascular endothelium and migration into the central nervous system. AVONEX (interferon beta-1a) enhances immunoregulatory cytokine production and reduces pro-inflammatory responses. These are typically used sequentially or as part of combination therapy strategies in MS management.","oneSentence":"TYSABRI blocks α4-integrin to prevent immune cells from crossing the blood-brain barrier, while AVONEX is interferon beta-1a that modulates immune response; together they reduce inflammation in multiple sclerosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:23.266Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (TYSABRI)"},{"name":"Clinically isolated syndrome suggestive of multiple sclerosis (AVONEX)"},{"name":"Relapsing multiple sclerosis (AVONEX)"}]},"trialDetails":[{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT05658497","phase":"","title":"Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)","status":"RECRUITING","sponsor":"Biogen","startDate":"2023-10-27","conditions":"Multiple Sclerosis","enrollment":908},{"nctId":"NCT00771043","phase":"PHASE4","title":"A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2008-11-01","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT01058005","phase":"PHASE3","title":"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis","status":"TERMINATED","sponsor":"Biogen","startDate":"2010-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":84},{"nctId":"NCT01071083","phase":"PHASE2","title":"Treatment Interruption of Natalizumab","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":175},{"nctId":"NCT01626248","phase":"","title":"Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control","status":"COMPLETED","sponsor":"John F. Foley, MD","startDate":"2012-07","conditions":"Multiple Sclerosis","enrollment":164},{"nctId":"NCT00030966","phase":"PHASE3","title":"Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2002-01","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TYSABRI and AVONEX","genericName":"TYSABRI and AVONEX","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TYSABRI blocks α4-integrin to prevent immune cells from crossing the blood-brain barrier, while AVONEX is interferon beta-1a that modulates immune response; together they reduce inflammation in multiple sclerosis. Used for Relapsing-remitting multiple sclerosis (TYSABRI), Clinically isolated syndrome suggestive of multiple sclerosis (AVONEX), Relapsing multiple sclerosis (AVONEX).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}